AGLE - Aeglea BioTherapeutics, Inc.
| Previous Close | 7.84 |
| Open | 7.91 |
| Bid | 7.33 x 800 |
| Ask | 8.55 x 800 |
| Day's Range | 7.76 - 8.00 |
| 52 Week Range | 5.99 - 9.45 |
| Volume | 55,981 |
| Avg. Volume | 53,393 |
| Market Cap | 230.725M |
| Beta (5Y Monthly) | 1.05 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.41 |
| Earnings Date | Nov 05, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 14.83 |
- GlobeNewswire
Aeglea BioTherapeutics Submits CTA Application for its Novel Engineered Human Enzyme Designed to Treat Homocystinuria (ACN00177)
AUSTIN, Texas, Jan. 13, 2020 -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing next-generation human enzyme therapeutics as.
- Simply Wall St.
Is Aeglea BioTherapeutics, Inc.'s (NASDAQ:AGLE) CEO Salary Justified?
Anthony Quinn became the CEO of Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) in 2017. This analysis aims first to...
- GlobeNewswire
Aeglea BioTherapeutics to Present at 38th Annual J.P. Morgan Healthcare Conference
AUSTIN, Texas, Jan. 06, 2020 -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing next-generation human enzyme therapeutics as.
- Insider Monkey
Hedge Funds Are Dumping Aeglea BioTherapeutics, Inc. (AGLE)
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. Insider Monkey finished processing more than 750 13F filings submitted by hedge funds and prominent investors. These filings show these funds' portfolio positions as of September […]
- Simply Wall St.
Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Insiders Increased Their Holdings
We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is...
- GlobeNewswire
Aeglea BioTherapeutics to Participate in Upcoming Investor Conferences
AUSTIN, Texas, Nov. 26, 2019 -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that engineers next-generation human enzymes to provide.
- GlobeNewswire
Aeglea BioTherapeutics Reports Third Quarter 2019 Financial Results and Corporate Highlights
AUSTIN, Texas, Nov. 06, 2019 -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that engineers next-generation human enzymes to provide.
- GlobeNewswire
Aeglea BioTherapeutics Strengthens Leadership Team with Appointment of Ravi M. Rao as Chief Medical Officer and Michael C. Hanley as Chief Commercial Officer
AUSTIN, Texas, Nov. 04, 2019 -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that engineers next-generation human enzymes to provide.
- Simply Wall St.
Will Aeglea BioTherapeutics (NASDAQ:AGLE) Spend Its Cash Wisely?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
- Simply Wall St.
Does Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Have A Volatile Share Price?
Anyone researching Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) might want to consider the historical volatility of the...
- GlobeNewswire
Aeglea BioTherapeutics Announces Positive 20-Dose Data for Pegzilarginase in Patients with Arginase 1 Deficiency at the 2019 SSIEM Symposium
Aeglea BioTherapeutics, Inc. (AGLE), a clinical-stage biotechnology company that engineers next-generation human enzymes to provide solutions for diseases with unmet medical need, today presented positive 20-dose data on 14 patients from the Company’s completed Phase 1/2 trial and ongoing Phase 2 open-label extension (OLE) trial for pegzilarginase in patients with Arginase 1 Deficiency (ARG1-D) at the 2019 Symposium of the Society for the Study of Inborn Errors of Metabolism (SSIEM). “We continue to see a transformative impact of pegzilarginase on plasma arginine control with accompanying improvements in important disease manifestations,” said Anthony G. Quinn, M.B. Ch.B., Ph.D., president and chief executive officer of Aeglea.
- GlobeNewswire
Aeglea BioTherapeutics to Present New 20-Dose Data for Pegzilarginase in Patients with Arginase 1 Deficiency at 2019 SSIEM Symposium
AUSTIN, Texas, Aug. 29, 2019 -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that engineers next-generation human enzymes to provide.
- GlobeNewswire
Aeglea BioTherapeutics Reports Second Quarter 2019 Financial Results and Corporate Highlights
FDA Breakthrough Therapy Designation Received for Pegzilarginase in Treatment of Arginase 1 Deficiency Dosed First Patient in Global Pivotal Phase 3 PEACE Trial New Data from.
- Benzinga
The Daily Biotech Pulse: Setback For Bristol-Myers Squibb, Gemphire Explodes, Lilly's Nasal Low Blood Sugar Drug
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 24) Acasti Pharma Inc (NASDAQ: ACST ) Cardiovascular Systems ...
- GlobeNewswire
Aeglea BioTherapeutics Receives FDA Breakthrough Therapy Designation for Pegzilarginase for Treatment of Arginase 1 Deficiency
Aeglea BioTherapeutics, Inc. (AGLE), a clinical-stage biotechnology company that engineers next-generation human enzymes to provide solutions for diseases with unmet medical need, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to the Company’s lead investigational therapy, pegzilarginase, for the treatment of Arginase 1 Deficiency (ARG1-D), a rare progressive disease presenting in early childhood that results in severe complications and early mortality. "The emerging clinical data demonstrating favorable effects of pegzilarginase treatment on both plasma arginine levels and important disease manifestations has led to the FDA’s designation of pegzilarginase as a breakthrough therapy," said Anthony G. Quinn, M.B. Ch.B, Ph.D., president and chief executive officer of Aeglea.
- Simply Wall St.
Can We See Significant Institutional Ownership On The Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Share Register?
If you want to know who really controls Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), then you'll have to look at the...
- GuruFocus.com
Aeglea Biotherapeutics Inc (AGLE) President & CEO Anthony G. Quinn Bought $196,535 of Shares
President & CEO of Aeglea Biotherapeutics Inc (NASDAQ:AGLE) Anthony G. Quinn bought 31,905 shares of AGLE on 06/14/2019 at an average price of $6.16 a share.
- Insider Monkey
Hedge Funds Have Never Been This Bullish On Aeglea BioTherapeutics, Inc. (AGLE)
It is already common knowledge that individual investors do not usually have the necessary resources and abilities to properly research an investment opportunity. As a result, most investors pick their illusory “winners” by making a superficial analysis and research that leads to poor performance on aggregate. Since stock returns aren't usually symmetrically distributed and index […]
- GlobeNewswire
Aeglea BioTherapeutics Doses First Patient in Pivotal Phase 3 PEACE Trial of Pegzilarginase in Arginase 1 Deficiency
Aeglea BioTherapeutics, Inc. (AGLE), a clinical-stage biotechnology company that engineers next-generation human enzymes to provide solutions for diseases with unmet medical need, today announced the dosing of the first patient in the Company’s Phase 3 PEACE (Pegzilarginase Effect on Arginase 1 Deficiency Clinical Endpoints) clinical trial. The pivotal trial is intended to further evaluate the efficacy and safety of pegzilarginase for the treatment of Arginase 1 Deficiency (ARG1-D), a progressive disease presenting in early childhood that results in severe complications and early mortality.
- GlobeNewswire
Aeglea BioTherapeutics to Participate in Upcoming Investor and Industry Conferences
AUSTIN, Texas, May 30, 2019 -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that engineers next-generation human enzymes to provide.
- TheStreet.com
These 3 Biotech Stocks Are Attracting Insider Buying
Volatility continues to pick up as trade tensions between the U.S. and China continue to escalate with no current end in sight. Add in EU elections and the coming departure of the prime minister in the U.
- GuruFocus.com
Aeglea Biotherapeutics Inc (AGLE) President & CEO Anthony G. Quinn Bought $180,028 of Shares
President & CEO of Aeglea Biotherapeutics Inc (NASDAQ:AGLE) Anthony G. Quinn bought 26,592 shares of AGLE on 05/22/2019 at an average price of $6.77 a share.
- Associated Press
Aeglea: 1Q Earnings Snapshot
On a per-share basis, the Austin, Texas-based company said it had a loss of 59 cents. Aeglea shares have dropped 6.5% since the beginning of the year. The stock has declined 28% in the last 12 months. ...
- GlobeNewswire
Aeglea BioTherapeutics Reports First Quarter 2019 Financial Results and Corporate Highlights
Statistically Significant Reductions in Plasma Arginine with Accompanying Clinical Improvements with Pegzilarginase in Phase 1/2 Reaffirm Pivotal Trial Design Gross Proceeds of.
- Simply Wall St.
Have Insiders Been Selling Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Shares?
It is not uncommon to see companies perform well in the years after insiders buy shares. On the other hand, we'd be remiss not to mention that insider sales have been known to precede tough periods for a business. So we'll take a look...
